We reported increased expression of hepatic mRNA SFRP5 in NAFLD patients than NL ones; and then, when we classified our NAFLD subjects in SS and NASH, we observed higher expression in the SS group than NL and also than NASH patients. Here, SFRP5 is linked to metabolic dysfunction-associated steatotic liver disease.